scispace - formally typeset
N

Nathalie Crokart

Researcher at Université catholique de Louvain

Publications -  16
Citations -  927

Nathalie Crokart is an academic researcher from Université catholique de Louvain. The author has contributed to research in topics: Tumor Oxygenation & Tumor microenvironment. The author has an hindex of 13, co-authored 16 publications receiving 857 citations.

Papers
More filters
Journal ArticleDOI

Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with Paclitaxel

TL;DR: In vivo, the targeting of anti-cancer drug to tumor endothelium by RGD-labeled NP is a promising approach and is demonstrated to be more effective in vitro and in vivo than taxol.
Journal ArticleDOI

Early reoxygenation in tumors after irradiation: determining factors and consequences for radiotherapy regimens using daily multiple fractions

TL;DR: It is observed that splitting a treatment of 18 Gy into two fractions separated by 4 h had a greater effect on tumor regrowth delay than when applied as a single dose, and the oxygen effect must be also considered to optimize the treatment strategy.
Journal ArticleDOI

Tumor radiosensitization by antiinflammatory drugs: evidence for a new mechanism involving the oxygen effect.

TL;DR: In this article, the effect of four NSAIDs (diclofenac, indomethacin, piroxicam, and NS-398) on tumor oxygenation was studied in murine TLT liver tumors and FSaII fibrosarcomas.
Journal ArticleDOI

The role of vessel maturation and vessel functionality in spontaneous fluctuations of T2*‐weighted GRE signal within tumors

TL;DR: It is demonstrated that adequate vessel functionality and advanced vessel maturation could explain at least in part the occurrence of spontaneous T2*w GRE signal fluctuations.
Journal ArticleDOI

Mechanism of reoxygenation after antiangiogenic therapy using SU5416 and its importance for guiding combined antitumor therapy.

TL;DR: The results show that the long-term inhibition of oxygen consumption is a potential novel target in this class of compounds and found that SU5416 potentiated tumor response to radiotherapy but not to chemotherapy.